You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies aim to develop robust methods for experiments analyzing thousands of tissue and plasma proteomes.
A team led by UCSF researchers found that no one viral lineage predominates in the region and that travel and social restrictions may stem spread.
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
The decision comes after Myriad requested expanded coverage for women with breast cancer seeking information about extending endocrine therapy.
The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types.
Promega will seek to expand use of the assay in Europe while it works through regulatory review of the test for companion diagnostic use in the US and Asia.
The company said clinical services revenues and diagnostic testing volumes fell during the quarter due to the negative impact of the COVID-19 pandemic.
The survey further characterized antibiotic resistance genes within these communities, suggesting that such an approach could aid in infection control efforts.
Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.
Avalon said it intends to establish a facility in the US for the manufacture and assembly of antibody and PCR-based detection systems.
Last week, GenomeWeb's readers were most interested in the CDC's new assay that can simultaneously detect the SARS-CoV-2 coronavirus and the influenza virus.
Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.
The company said it has scaled up production capacity to two million reactions per week and has the potential to scale up to three million reactions per week.
Phosphorus' test is authorized for use with saliva samples collected by healthcare providers or patients at home using DNA Genotek's collection kit.
The new method uses Takara Bio's SmartChip PCR instrument, chips, and reagents to run 5,184 reactions per chip in less than 30 minutes.
ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.
News items for the week of June 1, 2020.
An analysis of pediatric cancer survivors suggests subsequent neoplasm risk can increase after certain genotoxic treatments in those with DNA repair gene changes.
The test is designed to detect a nucleic acid sequence from the SARS-CoV-2 E gene in various respiratory specimens including nasal swabs.
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.
The company said it has also received Emergency Use Authorization from the US Food and Drug Administration for its nucleic acid extraction kit.
CDC Director Robert Redfield told a congressional subcommittee about the test, for which the center plans to seek Emergency Use Authorization from the FDA.
Ancient samples from more than a dozen archaeological sites suggests population movement from South America preceded by at least two earlier migration waves.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.